Claiming patent infringement, Pfizer Inc. has filed a complaint in the US District Court in Delaware, requesting an injunction to block Teva Pharmaceutical Industries Ltd from selling a generic form of its Zyvox antibiotic. The move follows Teva’s filing an abbreviated new drug application with the US Food and Drug Administration, seeking regulatory approval, which Pfizer claims is patent infringement. Zyvox is used to treat pneumonia and skin infections and has global sales of about $1.1 billion a year. The Teva generic would threaten Zyvox’s US sales, which totaled about $575 million. The Zyvox patent may be renewed until 2014, unless Teva can somehow invalidate it.
The IP Factor
Opinionated Intellectual Property News Blog with an Israel Slant
Michael Factor
[...] Source Tags: delaware, dispute, FDA, infringement, intellectual property, invalidation, Lawsuit, patent, patent infringement, pfizer, pneumonia, skin infections, sue, sued, teva, zyvox. [...]
iam IP professional from India
i need the updates on different US court cases on pharma
This blog focuses on Israel related developments.
I try to report on Teva since its Israel’s biggest firm and they are involved in a lot of litigation.
For US court cases on pharma, try Patently-O, IP Watchdog and the other US IP blogs, and look for specific Pharma blogs.
Good luck!
Sincerely yours,
Dr. Michael Factor